{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T13:32:35Z","timestamp":1781530355404,"version":"3.54.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T00:00:00Z","timestamp":1723420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T00:00:00Z","timestamp":1723420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Germline breast cancer susceptibility gene (g<jats:italic>BRCA<\/jats:italic>) mutation in patients with pancreatic cancer (PC) is not common in clinical practice. Therefore, factors that efficiently show g<jats:italic>BRCA<\/jats:italic> mutations and the real-world outcomes of olaparib maintenance therapy have not been fully established. In the present study, we clarified the indicators for the effective detection of g<jats:italic>BRCA<\/jats:italic> mutation and the efficacy and safety of olaparib as maintenance therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We retrospectively analyzed 84 patients with PC who underwent g<jats:italic>BRCA<\/jats:italic> testing (BRACAnalysis, Myriad Genetics, Salt Lake City, UT, USA) at our institute between January 2021 and March 2022. For each patient, clinical data were extracted from medical records.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The median patient age was 64 y (29\u201385 y), and 41 patients (48.8%) were male. The g<jats:italic>BRCA<\/jats:italic> mutations were identified in 10 (11.9%) patients; two patients had <jats:italic>BRCA1<\/jats:italic> mutation and eight had <jats:italic>BRCA2<\/jats:italic> mutation. All patients with g<jats:italic>BRCA<\/jats:italic> mutation had a family history of any cancer, and eight of them had a family history of Hereditary Breast and Ovarian Cancer syndrome (HBOC)-related cancer. The g<jats:italic>BRCA<\/jats:italic> mutation rate was higher for patients with PC with a family history of HBOC-related cancer compared to that in patients with PC having a family history of other cancers and no family history of cancer (22.9% vs. 4.1%; <jats:italic>P<\/jats:italic>\u2009=\u20090.014). In our study, eight out of 10 patients with g<jats:italic>BRCA<\/jats:italic>-positive PC received olaparib after platinum-based chemotherapy. The best responses to platinum-based chemotherapy included a complete response in one patient (12.5%) and a partial response in seven patients (87.5%). The median duration of treatment with platinum-based chemotherapy plus olaparib was 17.5 months (8\u201387 months), and the duration of treatment with olaparib maintenance therapy was 11 months (1\u201330 months). During olaparib maintenance therapy, three patients showed no disease progression. One of these three patients underwent conversion surgery after receiving olaparib for 12 months.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The g<jats:italic>BRCA<\/jats:italic> testing should be considered proactively, especially in patients with PC with a family history of HBOC-related cancer.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-024-12722-8","type":"journal-article","created":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T20:06:21Z","timestamp":1723493181000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinical significance of germline breast cancer susceptibility gene (gBRCA) testing and olaparib as maintenance therapy for patients with pancreatic cancer"],"prefix":"10.1186","volume":"24","author":[{"given":"Yasuharu","family":"Kawamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuo","family":"Yamai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Ikezawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Seiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ko","family":"Watsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeru","family":"Hirao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makiko","family":"Urabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yugo","family":"Kai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoji","family":"Takada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Mukai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasuku","family":"Nakabori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Uehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tazuko","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumie","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyoshi","family":"Ohkawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,12]]},"reference":[{"key":"12722_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17\u201348.","journal-title":"CA Cancer J Clin"},{"key":"12722_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"12722_CR3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41575-023-00856-2","volume":"21","author":"TF Stoop","year":"2024","unstructured":"Stoop TF, Theijse RT, Seelen LWF, Groot Koerkamp B, van Eijck CHJ, Wolfgang CL, et al. Preoperative chemotherapy, radiotherapy, and surgical decision-making in patients with borderline resectable and locally-advanced pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2024;21:101\u201324.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"12722_CR4","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1186\/s12885-023-11205-6","volume":"23","author":"R Takada","year":"2023","unstructured":"Takada R, Ikezawa K, Yamai T, Watsuji K, Seiki Y, Kawamoto Y, et al. Parallel administration of nanoliposomal irinotecan and levo-leucovorin for pancreatic cancer. BMC Cancer. 2023;23:711.","journal-title":"BMC Cancer"},{"key":"12722_CR5","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","volume":"402","author":"ZA Wainberg","year":"2023","unstructured":"Wainberg ZA, Melisi D, Macarulla T, Pazo Cid R, Chandana SR, De La Fouchardi\u00e8re C, et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet. 2023;402:1272\u201381.","journal-title":"Lancet"},{"key":"12722_CR6","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.gtc.2022.06.006","volume":"51","author":"H Saba","year":"2022","unstructured":"Saba H, Goggins M. Familial pancreatic cancer. Gastroenterol Clin North Am. 2022;51:561\u201375.","journal-title":"Gastroenterol Clin North Am"},{"key":"12722_CR7","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1053\/j.gastro.2021.01.220","volume":"160","author":"T Golan","year":"2021","unstructured":"Golan T, O\u2019Kane GM, Denroche RE, Raitses-Gurevich M, Grant RC, Holter S, et al. Genomic features and classification of homologous recombination deficient pancreatic ductal adenocarcinoma. Gastroenterology. 2021;160:2119\u2013e21329.","journal-title":"Gastroenterology"},{"key":"12722_CR8","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s00535-023-01986-9","volume":"58","author":"T Sakakida","year":"2023","unstructured":"Sakakida T, Ishikawa T, Doi T, Morita R, Kataoka S, Miyake H, et al. Genomic landscape and clinical features of rare subtypes of pancreatic cancer: analysis with the national database of Japan. J Gastroenterol. 2023;58:575\u201385.","journal-title":"J Gastroenterol"},{"key":"12722_CR9","first-page":"1105","volume":"52","author":"T Terashima","year":"2022","unstructured":"Terashima T, Morizane C, Ushiama M, Shiba S, Takahashi H, Ikeda M, et al. Germline variants in cancer-predisposing genes in pancreatic cancer patients with a family history of cancer. Jpn J Clin Oncol. 2022;52:1105\u201314.","journal-title":"Jpn J Clin Oncol"},{"key":"12722_CR10","doi-asserted-by":"publisher","first-page":"100881","DOI":"10.1016\/j.esmoop.2023.100881","volume":"8","author":"S Paiella","year":"2023","unstructured":"Paiella S, Azzolina D, Gregori D, Malleo G, Golan T, Simeone DM, et al. A systematic review and meta-analysis of germline BRCA mutations in pancreatic cancer patients identifies global and racial disparities in access to genetic testing. ESMO Open. 2023;8:100881.","journal-title":"ESMO Open"},{"key":"12722_CR11","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1158\/0008-5472.CAN-03-3823","volume":"64","author":"AP Klein","year":"2004","unstructured":"Klein AP, Brune KA, Petersen GM, Goggins M, Tersmette AC, Offerhaus GJ, et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res. 2004;64:2634\u20138.","journal-title":"Cancer Res"},{"key":"12722_CR12","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1158\/1078-0432.CCR-20-0418","volume":"26","author":"W Park","year":"2020","unstructured":"Park W, Chen J, Chou JF, Varghese AM, Yu KH, Wong W, et al. Genomic methods identify homologous recombination deficiency in pancreas adenocarcinoma and optimize treatment selection. Clin Cancer Res. 2020;26:3239\u201347.","journal-title":"Clin Cancer Res"},{"key":"12722_CR13","doi-asserted-by":"crossref","unstructured":"Yamai T, Ikezawa K, Sugimoto N, Urabe M, Kai Y, Takada R et al. Utility of comprehensive genomic profiling tests for patients with incurable pancreatic cancer in clinical practice. Cancers (Basel) 2023;15.","DOI":"10.3390\/cancers15030970"},{"issue":"6","key":"12722_CR14","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/em.22505","volume":"63","author":"C Shao","year":"2022","unstructured":"Shao C, Wan J, Lam FC, Tang H, Marley AR, Song Y, et al. A Comprehensive literature review and meta-analysis of the prevalence of pan-cancer BRCA mutations, homologous recombination repair gene mutations, and homologous recombination deficiencies. Environ Mol Mutagen. 2022;63(6):308\u201316.","journal-title":"Environ Mol Mutagen"},{"key":"12722_CR15","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.1200\/JCO.2014.59.7401","volume":"33","author":"S Holter","year":"2015","unstructured":"Holter S, Borgida A, Dodd A, Grant R, Semotiuk K, Hedley D, et al. Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma. J Clin Oncol. 2015;33:3124\u20139.","journal-title":"J Clin Oncol"},{"key":"12722_CR16","doi-asserted-by":"publisher","first-page":"103033","DOI":"10.1016\/j.ebiom.2020.103033","volume":"60","author":"K Mizukami","year":"2020","unstructured":"Mizukami K, Iwasaki Y, Kawakami E, Hirata M, Kamatani Y, Matsuda K, et al. Genetic characterization of pancreatic cancer patients and prediction of carrier status of germline pathogenic variants in cancer-predisposing genes. EBiomedicine. 2020;60:103033.","journal-title":"EBiomedicine"},{"key":"12722_CR17","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1001\/jamaoncol.2022.0476","volume":"8","author":"Y Momozawa","year":"2022","unstructured":"Momozawa Y, Sasai R, Usui Y, Shiraishi K, Iwasaki Y, Taniyama Y, et al. Expansion of cancer risk profile for BRCA1 and BRCA2 pathogenic variants. JAMA Oncol. 2022;8:871\u20138.","journal-title":"JAMA Oncol"},{"key":"12722_CR18","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s10038-022-01097-y","volume":"68","author":"H Matsubayashi","year":"2023","unstructured":"Matsubayashi H, Todaka A, Kawakami T, Hamauchi S, Yokota T, Higashigawa S, et al. Genetic medicine in companion diagnostics of germline BRCA testing of Japanese pancreatic cancer patients. J Hum Genet. 2023;68:81\u20136.","journal-title":"J Hum Genet"},{"key":"12722_CR19","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1093\/jjco\/hyad131","volume":"54","author":"T Kubo","year":"2024","unstructured":"Kubo T, Muramatsu J, Arihara Y, Murota A, Ishikawa K, Yoshida M, et al. Clinical characterization of patients with gBRCA1\/2 mutation-positive unresectable pancreatic cancer: a multicenter, prospective study. Jpn J Clin Oncol. 2024;54:47\u201353.","journal-title":"Jpn J Clin Oncol"},{"key":"12722_CR20","doi-asserted-by":"publisher","first-page":"175883592311891","DOI":"10.1177\/17588359231189127","volume":"15","author":"T Golan","year":"2023","unstructured":"Golan T, Casolino R, Biankin AV, Hammel P, Whitaker KD, Hall MJ, et al. Germline BRCA testing in pancreatic cancer: improving awareness, timing, turnaround, and uptake. Ther Adv Med Oncol. 2023;15:17588359231189127.","journal-title":"Ther Adv Med Oncol"},{"key":"12722_CR21","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.3390\/cancers15112955","volume":"15","author":"F Keane","year":"2023","unstructured":"Keane F, O\u2019Connor CA, Park W, Seufferlein T, O\u2019Reilly EM. Pancreatic cancer: BRCA targeted therapy and beyond. Cancers (Basel). 2023;15:2955.","journal-title":"Cancers (Basel)"},{"key":"12722_CR22","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s10038-023-01153-1","volume":"68","author":"A Ueki","year":"2023","unstructured":"Ueki A, Yoshida R, Kosaka T, Matsubayashi H. Clinical risk management of breast, ovarian, pancreatic, and prostatic cancers for BRCA1\/2 variant carriers in Japan. J Hum Genet. 2023;68:517\u201326.","journal-title":"J Hum Genet"},{"key":"12722_CR23","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3892\/mco.2021.2258","volume":"14","author":"F Fujisawa","year":"2021","unstructured":"Fujisawa F, Tamaki Y, Inoue T, Nakayama T, Yagi T, Kittaka N, et al. Prevalence of BRCA1 and BRCA2 mutations in Japanese patients with triple-negative breast cancer: a single institute retrospective study. Mol Clin Oncol. 2021;14:96.","journal-title":"Mol Clin Oncol"},{"key":"12722_CR24","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.pan.2023.10.017","volume":"23","author":"H Kitamura","year":"2023","unstructured":"Kitamura H, Morizane C, Tanabe N, Go I, Maruki Y, Ohba A, et al. Clinical features of germline BRCA1\/2 or ATM pathogenic variant positive pancreatic cancer in Japan. Pancreatology. 2023;23:964\u20139.","journal-title":"Pancreatology"},{"key":"12722_CR25","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/cas.15518","volume":"114","author":"K Oda","year":"2023","unstructured":"Oda K, Aoki D, Tsuda H, Nishihara H, Aoyama H, Inomata H, et al. Japanese nationwide observational multicenter study of tumor BRCA1\/2 variant testing in advanced ovarian cancer. Cancer Sci. 2023;114:271\u201380.","journal-title":"Cancer Sci"},{"key":"12722_CR26","doi-asserted-by":"publisher","first-page":"104350","DOI":"10.1016\/j.ejmg.2021.104350","volume":"64","author":"DH Marmolejo","year":"2021","unstructured":"Marmolejo DH, Wong MYZ, Bajalica-Lagercrantz S, Tischkowitz M, Balma\u00f1a J, extended ERN-GENTURIS Thematic Group 3. Overview of hereditary breast and ovarian cancer (HBOC) guidelines across Europe. Eur J Med Genet. 2021;64:104350.","journal-title":"Eur J Med Genet"},{"key":"12722_CR27","first-page":"1265","volume":"52","author":"S Ohsumi","year":"2022","unstructured":"Ohsumi S, Nakamura S, Miyata H, Watanabe C, Den H, Arai M. Risk-reducing mastectomy for women with hereditary breast and ovarian cancer (HBOC): Analytical results of data from the Japanese Organization of HBOC. Jpn J Clin Oncol. 2022;52:1265\u20139.","journal-title":"Jpn J Clin Oncol"},{"key":"12722_CR28","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1093\/jjco\/hyad020","volume":"53","author":"M Nagashima","year":"2023","unstructured":"Nagashima M, Ishikawa T, Asami Y, Hirose Y, Shimada K, Miyagami S, et al. Risk-reducing salpingo-oophorectomy for Japanese women with hereditary breast and ovarian cancer: a single-institution 10-year experience. Jpn J Clin Oncol. 2023;53:472\u20139.","journal-title":"Jpn J Clin Oncol"},{"key":"12722_CR29","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1038\/bjc.2014.418","volume":"111","author":"T Golan","year":"2014","unstructured":"Golan T, Kanji ZS, Epelbaum R, Devaud N, Dagan E, Holter S, et al. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer. 2014;111:1132\u20138.","journal-title":"Br J Cancer"},{"key":"12722_CR30","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1093\/jnci\/djy024","volume":"110","author":"MA Lowery","year":"2018","unstructured":"Lowery MA, Wong W, Jordan EJ, Lee JW, Kemel Y, Vijai J, et al. Prospective evaluation of germline alterations in patients with exocrine pancreatic neoplasms. J Natl Cancer Inst. 2018;110:1067\u201374.","journal-title":"J Natl Cancer Inst"},{"key":"12722_CR31","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41575-023-00840-w","volume":"21","author":"ZI Hu","year":"2024","unstructured":"Hu ZI, O\u2019Reilly EM. Therapeutic developments in pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2024;21:7\u201324.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"12722_CR32","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","volume":"186","author":"CJ Halbrook","year":"2023","unstructured":"Halbrook CJ, Lyssiotis CA, Pasca di Magliano M, Maitra A. Pancreatic cancer: advances and challenges. Cell. 2023;186:1729\u201354.","journal-title":"Cell"},{"key":"12722_CR33","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","volume":"381","author":"T Golan","year":"2019","unstructured":"Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381:317\u201327.","journal-title":"N Engl J Med"},{"issue":"55","key":"12722_CR34","first-page":"603","volume":"17","author":"MA Tempero","year":"2019","unstructured":"Tempero MA. NCCN guidelines updates: pancreatic cancer. J Natl Compr Canc Netw. 2019;17(55):603\u20135.","journal-title":"J Natl Compr Canc Netw"},{"key":"12722_CR35","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (Version 1 1). 2009;45:228\u201347.","journal-title":"Eur J Cancer (Version 1 1)"},{"key":"12722_CR36","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transpl. 2013;48:452\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"12722_CR37","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.addr.2021.02.010","volume":"171","author":"T Golan","year":"2021","unstructured":"Golan T, Atias D, Stossel C, Raitses-Gurevich M. Patient-derived xenograft models of BRCA-associated pancreatic cancers. Adv Drug Deliv Rev. 2021;171:257\u201365.","journal-title":"Adv Drug Deliv Rev"},{"key":"12722_CR38","doi-asserted-by":"publisher","first-page":"3929","DOI":"10.1200\/JCO.21.01604","volume":"40","author":"HL Kindler","year":"2022","unstructured":"Kindler HL, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, et al. Overall survival results from the POLO trial: a phase III study of active maintenance olaparib versus placebo for germline BRCA-mutated metastatic pancreatic cancer. J Clin Oncol. 2022;40:3929\u201339.","journal-title":"J Clin Oncol"},{"key":"12722_CR39","doi-asserted-by":"publisher","first-page":"3963","DOI":"10.1245\/s10434-020-08469-8","volume":"27","author":"T Golan","year":"2020","unstructured":"Golan T, Barenboim A, Lahat G, Nachmany I, Goykhman Y, Shacham-Shmueli E, et al. Increased rate of complete pathologic response after neoadjuvant FOLFIRINOX for BRCA mutation carriers with borderline resectable pancreatic cancer. Ann Surg Oncol. 2020;27:3963\u201370.","journal-title":"Ann Surg Oncol"},{"key":"12722_CR40","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1093\/jjco\/hyz141","volume":"49","author":"H Shimmura","year":"2019","unstructured":"Shimmura H, Kuramochi H, Jibiki N, Katagiri S, Nishino T, Araida T. Dramatic response of FOLFIRINOX regimen in a collision pancreatic adenocarcinoma patient with a germline BRCA2 mutation: a case report. Jpn J Clin Oncol. 2019;49:1049\u201354.","journal-title":"Jpn J Clin Oncol"},{"key":"12722_CR41","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1200\/JCO.19.02931","volume":"38","author":"EM O\u2019Reilly","year":"2020","unstructured":"O\u2019Reilly EM, Lee JW, Zalupski M, Capanu M, Park J, Golan T, et al. Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA\/PALB2 mutation. J Clin Oncol. 2020;38:1378\u201388.","journal-title":"J Clin Oncol"},{"key":"12722_CR42","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/S2468-1253(20)30330-7","volume":"6","author":"V Kunzmann","year":"2021","unstructured":"Kunzmann V, Siveke JT, Alg\u00fcl H, Goekkurt E, Siegler G, Martens U, et al. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6:128\u201338.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"12722_CR43","doi-asserted-by":"publisher","first-page":"4733","DOI":"10.3390\/cancers13184733","volume":"13","author":"R Takada","year":"2021","unstructured":"Takada R, Ikezawa K, Daiku K, Maeda S, Abe Y, Urabe M, et al. The survival benefit of chemoradiotherapy following induction chemotherapy with gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer. Cancers (Basel). 2021;13:4733.","journal-title":"Cancers (Basel)"},{"key":"12722_CR44","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyad176","author":"K Ikezawa","year":"2023","unstructured":"Ikezawa K, Urabe M, Kai Y, Takada R, Akita H, Nagata S, et al. Comprehensive review of pancreatic acinar cell carcinoma: epidemiology, diagnosis, molecular features, and treatment. Jpn J Clin Oncol. 2023. https:\/\/doi.org\/10.1093\/jjco\/hyad176.","journal-title":"Jpn J Clin Oncol"},{"key":"12722_CR45","doi-asserted-by":"publisher","first-page":"5038","DOI":"10.1245\/s10434-022-11503-6","volume":"29","author":"Y Ushida","year":"2022","unstructured":"Ushida Y, Inoue Y, Oba A, Mie T, Ito H, Ono Y, et al. Optimizing indications for conversion surgery based on analysis of 454 consecutive Japanese cases with unresectable pancreatic cancer who received modified FOLFIRINOX or gemcitabine plus nab-paclitaxel: a single-center retrospective study. Ann Surg Oncol. 2022;29:5038\u201350.","journal-title":"Ann Surg Oncol"},{"key":"12722_CR46","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouch\u00e9 O, Guimbaud R, B\u00e9couarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817\u201325.","journal-title":"N Engl J Med"},{"issue":"19","key":"12722_CR47","doi-asserted-by":"publisher","first-page":"5895","DOI":"10.3390\/jcm11195895","volume":"11","author":"S Sadaka","year":"2022","unstructured":"Sadaka S, Iwashita T, Fujii H, Kato-Hayashi H, Ohata K, Uemura S, et al. Impact of first-line FOLFIRINOX-induced peripheral neuropathy on the efficacy of second-line GnP in patients with unresectable advanced pancreatic cancer. J Clin Med. 2022;11(19):5895.","journal-title":"J Clin Med"},{"key":"12722_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5387\/fms.2021-32","volume":"68","author":"M Sugimoto","year":"2022","unstructured":"Sugimoto M, Takagi T, Suzuki R, Konno N, Asama H, Sato Y, et al. Drug treatment for chemotherapy-induced peripheral neuropathy in patients with pancreatic cancer. Fukushima J Med Sci. 2022;68:1\u201310.","journal-title":"Fukushima J Med Sci"},{"key":"12722_CR49","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1186\/s12885-021-09069-9","volume":"21","author":"M Sugimoto","year":"2021","unstructured":"Sugimoto M, Takagi T, Suzuki R, Konno N, Asama H, Sato Y, et al. Mirogabalin vs Pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients. BMC Cancer. 2021;21:1319.","journal-title":"BMC Cancer"},{"key":"12722_CR50","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s12328-022-01741-2","volume":"16","author":"K Okada","year":"2023","unstructured":"Okada K, Uemura K, Okamoto W, Sumiyoshi T, Shintakuya R, Otsuka H, et al. Pathologic complete response following FOLFIRINOX and olaparib treatment for hepatic metastasized pancreatic ductal adenocarcinoma with a germline BRCA mutation. Clin J Gastroenterol. 2023;16:283\u20138.","journal-title":"Clin J Gastroenterol"},{"key":"12722_CR51","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1158\/2159-8290.CD-22-0412","volume":"13","author":"C Stossel","year":"2023","unstructured":"Stossel C, Raitses-Gurevich M, Atias D, Beller T, Glick Gorman Y, Halperin S, et al. Spectrum of response to platinum and PARP inhibitors in germline BRCA-associated pancreatic cancer in the clinical and preclinical setting. Cancer Discov. 2023;13:1826\u201343.","journal-title":"Cancer Discov"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12722-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-12722-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12722-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T08:14:50Z","timestamp":1723536890000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-12722-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,12]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["12722"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-12722-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,12]]},"assertion":[{"value":"10 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study conformed to the Declaration of Helsinki guidelines and was approved by the Ethical Review Committee of the Osaka International Cancer Institute (Approval number: 20148-3). Due to the retrospective nature of this study, the requirement for informed consent and consent to participate was waived using the opt-out method on our website. A waiver of informed consent was granted by the Institutional Review Board of Osaka International Cancer Institute.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Yamai reports honoraria for lectures from Taiho Pharmaceutical and Yakult Honsha. Ikezawa reports honoraria for lectures from Taiho Pharmaceutical, Yakult Honsha, Ono Pharmaceutical, MSD, Myriad Genetics, ASAHI KASEI PHARMA, Nihon Servier, AstraZeneca and Incyte Biosciences Japan, and research funding from ASKA Pharmaceutical. Takada reports honoraria for lectures from Taiho Pharmaceutical, Hisamitsu Pharmaceutical, Novartis, Myriad Genetics and TEIJIN PHARMA. Ohkawa reports honoraria for lectures from Eisai, Chugai Pharmaceutical, Yakult Honsha, Incyte Biosciences Japan, Takeda, Gilead, AstraZeneca and Hisamitsu, and research grants from Towa Pharmaceutical and Sumitomo Chemical. The other authors have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1000"}}